Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;1(3):437-443.
doi: 10.3892/mco.2013.80. Epub 2013 Feb 28.

Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma

Akira Iyoda  1 , Shi-Xu Jiang  2 , William D Travis  3 , Naomi Kurouzu  1 , Fumihiro Ogawa  1 , Hideki Amano  1 , Yuichi Sato  4 , Valerie W Rusch  5 , Makoto Saegusa  2 , Yukitoshi Satoh  1
Affiliations

Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma

Akira Iyoda et al. Mol Clin Oncol. 2013 May.

Abstract

The prognosis of patients with large-cell neuroendocrine carcinoma (LCNEC) of the lung is extremely poor and the optimal treatment for these patients has yet to be determined. In this study, we described the clinicopathological characteristics of LCNECs and compared the prognoses of corresponding stages determined by the guidelines of the 6th and 7th editions of the TNM classification of malignant tumors. Clinical data from 42 patients diagnosed with primary LCNEC who underwent treatment at Kitasato University Hospital between 1991 and 2009 were retrospectively analyzed. On follow-up of 42 patients, 22 (52.4%) had confirmed recurrent tumors, including 8 patients with mediastinal lymph node recurrences and 19 with distant metastases. The sites of distant metastases included the brain in 8, bone in 8, liver in 7, lungs in 5 and adrenal glands in 4 patients. For all the patients, the 5-year overall survival rate was 34.7% and the 5-year disease-free survival rate was 32.9%. The 5-year overall survival rates of patients with stage I cancers according to the 6th and 7th staging editions was 51.3% (6th n=18, 7th n=16). Thirteen of 42 patients (31.0%) also had metachronous or synchronous primary cancers. Patients with LCNEC had poor outcomes, even those with stage I tumors classified according to the 7th edition of the TNM classification. Therefore, frequent recurrences in addition to metachronous or synchronous primary cancers in patients with LCNEC should be treated.

Keywords: TNM stage; large cell; neuroendocrine; outcome; prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Overall survival curves of patients with large cell neuroendocrine carcinoma (LCNEC) according to the 6th edition of the TNM classification of malignant tumors. (B) Disease-free survival curves of patients with LCNEC according to the 6th edition of the TNM classification of malignant tumors. (C) Overall survival curves of patients with LCNEC according to the 7th edition of the TNM classification of malignant tumors. (D) Disease-free survival curves of patients with LCNEC according to the 7th edition of the TNM classification of malignant tumors.
See this image and copyright information in PMC

References

    1. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, editors. World Health Organization International Histological Classification of Tumors, XIII. 3rd edition. Springer-Verlag; Berlin/Heidelberg: 1999. Histological Typing of Lung and Pleural Tumours.
    1. Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T. Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg. 2007;84:702–707. - PubMed
    1. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer. 2001;91:1992–2000. - PubMed
    1. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24:70–76. - PubMed
    1. Iyoda A, Hiroshima K, Moriya Y, et al. Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity. Ann Thorac Surg. 2004;77:1891–1895. - PubMed

LinkOut - more resources